Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
DIVISLAB
Dr. Kiran Satchandra Divi B. Pharm., M.Pharm · Hyderabad, India · 11,565 employees
₹7,784.50
▲+4.84%DIVISLAB.NS, a leading Indian pharmaceutical company, continues to trade near its 52-week highs, fueled by its robust revenue growth and strong profit margins, despite analyst consensus holding a neutral view.
Exchange
NSI
Currency
INR
Day range
₹7,428.50 – ₹7,818.50
52-week range
₹5,636.50 – ₹7,818.50
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis60% confidence
Trading near the upper third of its 1-year range may suggest the stock might be somewhat overvalued, considering its P/E of 80.65.
0.4% below the 1-year high · trend up
Hedge-fund memo
Today
4.84% gain today, driven by institutional buying, as the stock breached its 52-week high.
This week
The stock has maintained its strong momentum over the past week, with 7.35% gain, driven by robust revenue growth.
This month
Year-to-date, the stock has gained 32.17% as investors seek growth opportunities.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Neutral
3 headlines · 2 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 3 of 4 recent quarters (EPS actual vs. consensus).
28.31 vs 26.44
7.07% surprise
24.0653 vs 23.28455
3.35% surprise
25.97 vs 22.211
16.92% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| DIVISLAB | 2.07T | 80.65 | 16.19% | 28.75% | 9.50% |
| DRREDDY | 951.54B | 28.74 | 8.84% | 4.25% | -5.60% |
| CIPLA | 1.19T | 35.31 | — |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory risks in the Indian pharmaceutical sector
Mitigation: Adhere to regulatory guidelines and engage in ongoing R&D to stay competitive
Dependence on a few key products for revenue
Mitigation: Diversify product portfolio and expand into new markets
High competition in the generic medicines space
Mitigation: Invest in R&D to differentiate its offerings and strengthen its market position
Business intelligence
Competitive moat
Its diversified product portfolio, strong research capabilities, and extensive distribution network serve as a strong competitive moat in the Indian pharmaceutical market.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
No notable recent activity flagged.
Catalyst calendar
Q2-Q3 CY-2024 results
Thesis builder
Bull case
DIVISLAB continues to benefit from its strong track record, robust revenue growth, and increasing profitability.
Base case
Neutral analyst consensus reflects a mixed sentiment, highlighting concerns over overvaluation.
Bear case
The healthcare sector's inherent risks, intense competition, and potential regulatory changes might impact the company's growth trajectory.
Time horizon
6-12 months
Est. CAGR
approx 10-15%
Entry (qual.)
Invest at current levels, weighing risks and potential opportunities.
Exit (qual.)
Consider selling if the stock breaches critical support levels or if a more robust opportunity arises.
Overall conviction 60%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how DIVISLAB fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain DIVISLAB for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
—
Closely monitor the stock's valuation and performance indicators before making any investment decisions.
TradingView·2d ago·large multi-year AI deal
TradingView·4d ago·steady revenue growth shown
equitypandit.com·5d ago·weekly outlookяз growth prospects
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
20.49 vs 22.43
-8.65% surprise
| 12.55% |
| 3.50% |
| LUPIN | 1.12T | 21.02 | 26.91% | 24.22% | 31.90% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹7,428.50
Resistance (day/52w high)
₹7,818.50
Volume
11,58,117
Trend
up
RSI (14)
85
MACD
bullish
MA cross
golden
50-day MA
₹6,845.05
200-day MA
₹6,473.97
vs 200-DMA
20.2%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.